Cytomedix to Exhibit At the 21st Annual Symposium On Advanced Wound Care (SAWC) April...

Cytomedix to Exhibit At the 21st Annual Symposium On Advanced Wound Care (SAWC)
April 24-27, 2008

ROCKVILLE, Md., April 10, 2008 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF),
today announced that it will be exhibiting at the 21st Annual Symposium on
Advanced Wound Care (SAWC) from April 24 through April 27, 2008 at the San Diego
Convention Center in San Diego, Ca.

The SAWC is the largest gathering of multidisciplinary wound care clinicians in
the United States. The conference targets physicians, nurses, physical
therapists, researchers, podiatrists, dieticians, and members of the medical
industry involved in wound healing or wound care issues. The conference provides
attendees who study and treat wounds with state-of-the-art reviews of clinical
problems and research information.

"We look forward to exhibiting at this prestigious event," said Kshitij Mohan,
Ph.D., Chairman and Chief Executive Officer of Cytomedix, Inc. "Our
participation in this symposium comes at a time when we are proceeding with the
launch of our AutoloGel(tm) System as planned, and provides an excellent venue
for demonstrating this unique wound management system utilizing platelet rich
plasma (PRP) gel for use in a wide variety of exuding wounds, including diabetic
ulcers, leg ulcers and pressure ulcers and other surgically or mechanically
debrided wounds."

ABOUT CYTOMEDIX

Cytomedix, Inc. is a biotechnology company specializing in processes and
products derived from autologous platelet releasates for use on wounds and other
applications. The current offering is the AutoloGel(tm) System, a process that
utilizes an autologous platelet gel composed of multiple growth factors, other
platelet releasates, and fibrin matrix. Additional information regarding
Cytomedix is available at: http://www.cytomedix.com.

SAFE HARBOR STATEMENT

Statements contained in this press release not relating to historical facts are
forward-looking statements that are intended to fall within the safe harbor rule
for such statements under the Private Securities Litigation Reform Act of 1995.
The information contained in the forward-looking statements is inherently
uncertain, and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict or control,
including among others, the success of new sales initiatives, governmental
regulation, acceptance by the medical community, and competition.

These forward-looking statements are subject to known and unknown risks and
uncertainties that could cause actual events to differ from the forward-looking
statements. More information about some of these risks and uncertainties may be
found in the reports filed with the Securities and Exchange Commission by
Cytomedix, Inc. Except as is expressly required by the federal securities laws,
Cytomedix undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, changed circumstances or
future events or for any other reason.

-0-
CONTACT: Cytomedix, Inc.
Kshitij Mohan, Ph.D., Chairman and CEO
240-499-2680

The Wall Street Group, Inc.
Ron Stabiner
212-888-4848